AAAAAA
Results:
1-19
|
Results: 19
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A PHARMACOECONOMIC PERSPECTIVE, Drugs & aging, 10(2), 1997, pp. 107-118
Authors:
JORGENSEN T
KANAGASINGAM Y
KAALHUS O
TVETER KJ
BRYNE M
SKJORTEN F
BERNER A
DANIELSEN HE
Citation: T. Jorgensen et al., PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGE D2) PROSTATE-CANCER - EXPERIENCE FROM THE SCANDINAVIAN PROSTATIC-CANCER GROUP STUDY-2, The Journal of urology, 158(1), 1997, pp. 164-170
Authors:
YOGESAN K
JORGENSEN T
ALBREGTSEN F
TVETER KJ
DANIELSEN HE
Citation: K. Yogesan et al., ENTROPY-BASED TEXTURE ANALYSIS OF CHROMATIN STRUCTURE IN ADVANCED PROSTATE-CANCER, Cytometry, 24(3), 1996, pp. 268-276
Authors:
JORGENSEN T
YOGESAN K
TVETER KJ
SKJORTEN F
DANIELSEN HE
Citation: T. Jorgensen et al., NUCLEAR TEXTURE ANALYSIS - A NEW PROGNOSTIC TOOL IN METASTATIC PROSTATE-CANCER, Cytometry, 24(3), 1996, pp. 277-283
Authors:
SVINDLAND A
ERI LM
TVETER KJ
Citation: A. Svindland et al., MORPHOMETRY OF BENIGN PROSTATIC HYPERPLASIA DURING ANDROGEN SUPPRESSIVE THERAPY - RELATIONSHIPS AMONG EPITHELIAL CONTENT, PSA DENSITY, AND CLINICAL OUTCOME, Scandinavian journal of urology and nephrology, 30, 1996, pp. 113-117
Authors:
ERI LM
HAUG E
TVETER KJ
Citation: Lm. Eri et al., EFFECTS ON THE ENDOCRINE SYSTEM OFLONG-TERM TREATMENT WITH THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, Scandinavian journal of clinical & laboratory investigation, 56(4), 1996, pp. 319-325
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - REPLY, The Journal of urology, 156(1), 1996, pp. 184-185
Authors:
MALMSTROM PU
RINTALA E
WAHLQVIST R
HELLSTROM P
HELLSTEN S
HANNISDAL E
ALFTHAN O
RUSK J
OPAS MA
JAUHIAINEN K
OTTELIN J
PERMI J
SALMELA H
TAINIO H
TALJA M
TUHKANEN K
VIITANEN J
BREVIK B
HOEG OM
JOHANNESSEN NB
FARSUND T
MEDBY PC
MURI O
FOSSA SD
OUS S
SANDER S
TVETER KJ
OMLAND H
STEINSVIK E
URNES T
WAALER G
OGREID P
OSTREM T
ANDERSSON L
EDSMYR F
EKMAN P
GUSTAFSON H
NORMING U
WIJKSTROM H
KARLBERG L
KIHL B
LINDEBORG T
Citation: Pu. Malmstrom et al., 5-YEAR FOLLOW-UP OF A PROSPECTIVE TRIAL OF RADICAL CYSTECTOMY AND NEOADJUVANT CHEMOTHERAPY - NORDIC CYSTECTOMY TRIAL-I, The Journal of urology, 155(6), 1996, pp. 1903-1906
Authors:
JORGENSEN T
MULLER C
KAALHUS O
DANIELSEN HE
TVETER KJ
Citation: T. Jorgensen et al., EXTENT OF DISEASE BASED ON INITIAL BONE-SCAN - IMPORTANT PROGNOSTIC PREDICTOR FOR PATIENTS WITH METASTATIC PROSTATIC-CANCER - EXPERIENCE FROM THE SCANDINAVIAN PROSTATIC-CANCER GROUP-STUDY NO-2 (SPCG-2), European urology, 28(1), 1995, pp. 40-46
Authors:
BERGE V
ERI LM
TVETER KJ
Citation: V. Berge et al., COMPLICATIONS OF INVASIVE, URODYNAMIC EXAMINATIONS AND PROSTATE BIOPSIES IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, Scandinavian journal of urology and nephrology, 1995, pp. 95-98
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(3), 1995, pp. 923-934
Authors:
JORGENSEN T
BERNER A
KAALHUS O
TVETER KJ
DANIELSEN HE
BRYNE M
Citation: T. Jorgensen et al., UP-REGULATION OF THE OLIGOSACCHARIDE SIALYL LEWIS(X) - A NEW PROGNOSTIC PARAMETER IN METASTATIC PROSTATE-CANCER, Cancer research, 55(9), 1995, pp. 1817-1819
Authors:
ERI LM
HAUG E
TVETER KJ
Citation: Lm. Eri et al., EFFECTS ON THE ENDOCRINE SYSTEM OF LONG-TERM TREATMENT WITH THE NONSTEROIDAL ANTIANDROGEN CASODEX IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, British Journal of Urology, 75(3), 1995, pp. 335-340
Authors:
JORGENSEN T
YOGESAN K
SKJORTEN F
BERNER A
TVETER KJ
DANIELSEN HE
Citation: T. Jorgensen et al., HISTOPATHOLOGICAL GRADING AND DNA-PLOIDY AS PROGNOSTIC MARKERS IN METASTATIC PROSTATIC-CANCER, British Journal of Cancer, 71(5), 1995, pp. 1055-1060
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE ANTIANDROGEN CASODEX IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, European urology, 26(3), 1994, pp. 219-226
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 152(2), 1994, pp. 448-452
Authors:
JORGENSEN T
TVETER KJ
JORGENSEN LH",WAHLQUIST,SKJEGGESTAD,HOISAETER,DEHLIN,VAAGE,KAPSTAD,MALME,URNES,WAALER,LUDVIGSEN,OTNES,OMLAND,BRATLIEJENSEN,HAGEN,STEINSVIK,HAVELAND,MORTENSEN,JOHANSSON,HEDLUND,HAHNE,NORLEN,HAGBERG,SANDIN,WEDMAN,DALEN
Citation: T. Jorgensen et al., TOTAL ANDROGEN SUPPRESSION - EXPERIENCE FROM THE SCANDINAVIAN PROSTATIC-CANCER GROUP-STUDY NO-2, European urology, 24(4), 1993, pp. 466-470
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 150(2), 1993, pp. 359-364
Authors:
ERI LM
TVETER KJ
Citation: Lm. Eri et Kj. Tveter, A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE ANTIANDROGEN CASODEX AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 150(1), 1993, pp. 90-94
Risultati:
1-19
|